If you have been watching Sarepta Therapeutics (SRPT), this week's headlines have probably caught your eye. Multiple law firms have announced class action lawsuits against the company, following ...

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

The FDA’s shift on Elevidys sends a message: boldness, scientific rigor and urgency are essential in confronting rare ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) and reminds investors of ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

Jefferies analysts said these detailed safety outcomes confirm the gene therapy's positive risk/benefit profile in ambulatory ...

Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients who can walk be allowed to take its gene therapy Elevidys again.

The stock has been in free fall since safety issues derailed a gene therapy analysts had expected to achieve blockbuster ...

Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts attributed in part to a milestone payment for its controversial gene therapy ...